Carbapenem-resistant Enterobacterales: Difference between revisions
From IDWiki
(Created page with "== Management == * First-line includes meropenem-vaborbactam or ceftazidime-avibactam, directed by susceptibility resultsCiteRef:paul2022eu * For metallo-β-lactamases or extensively resistant bacteria, consider cefiderocol * For non-severe infections, consider aminoglycosides, including plazomicin; tigecycline would be second-line, though it can be considered in pneumonia Category:Antimicrobial resistance") |
No edit summary |
||
| Line 2: | Line 2: | ||
* First-line includes [[meropenem-vaborbactam]] or [[ceftazidime-avibactam]], directed by susceptibility results[[CiteRef:paul2022eu]] |
* First-line includes [[meropenem-vaborbactam]] or [[ceftazidime-avibactam]], directed by susceptibility results[[CiteRef:paul2022eu]] |
||
* For metallo-β-lactamases or extensively resistant bacteria, consider [[cefiderocol]] |
* For metallo-β-lactamases or extensively resistant bacteria, consider [[cefiderocol]] or [[aztreonam]] plus [[ceftazidime-avibactam]] |
||
* For non-severe infections, consider [[aminoglycosides]], including [[plazomicin]]; [[tigecycline]] would be second-line, though it can be considered in pneumonia |
* For non-severe infections, consider [[aminoglycosides]], including [[plazomicin]]; [[tigecycline]] would be second-line, though it can be considered in pneumonia |
||
Latest revision as of 02:27, 14 November 2024
Management
- First-line includes meropenem-vaborbactam or ceftazidime-avibactam, directed by susceptibility resultsCiteRef:paul2022eu
- For metallo-β-lactamases or extensively resistant bacteria, consider cefiderocol or aztreonam plus ceftazidime-avibactam
- For non-severe infections, consider aminoglycosides, including plazomicin; tigecycline would be second-line, though it can be considered in pneumonia
